13-valent pneumococcal conjugate vaccine (Wuhan Bravovax)

13价肺炎球菌结合疫苗（武汉博沃生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug Name13-valent pneumococcal conjugate vaccine (Wuhan Bravovax)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccineVaccines > Application > Prophylactic vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMeningitisSepsisPneumonia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Bravovax Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Bravovax Co LtdLiaoning Chengda Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMeningitisSepsisPneumonia +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A